Bavarian Nordic opjusterer sine økonomiske forventninger til 2026 efter stærke resultater inden for Travel Health

Bavarian Nordic has upgraded its 2026 financial expectations following stronger-than-expected Travel Health segment performance. The company now forecasts Travel Health revenue of approximately DKK 3,400 million (up from DKK 3,000 million), driven primarily by increased rabies vaccine sales in the USA due to elevated animal rabies activity. Total 2026 revenue is now expected to reach approximately DKK 6,100 million with an EBITDA margin of approximately 32%, compared to previous guidance of DKK 5,700 million and 30% margin.